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Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
in the world. More deaths have been documented due to HNSCC in comparison to 
cervical cancer, melanoma, or Hodgkin’s lymphoma. The 5-year survival rate is only 
50% which is poor in comparison to breast cancer or melanoma.1  
Oral cancer is a subgroup of head and neck malignant neoplasms that includes 
carcinomas arising from the mucosal lining of the lips, the buccal mucosa, the 
retromolar trigone, the alveolar ridges, the anterior two- thirds of the tongue, the floor 
of the mouth, and the hard palate. Although oropharynx refers to the posterior third of 
the tongue, the soft palate and uvula, the tonsils, and the upper part of the posterior 
pharyngeal wall, malignant neoplasms involving oral cavity and oropharynx have 
been categorized together in the codes C00-C14 in the World Health Organization 
(WHO) International Classification of Diseases, 10th Revision. Numerous types of 
malignant neoplasms affect the oral cavity and oropharynx, but squamous cell 
carcinoma (SCC) that arises from the mucosal epithelial lining, accounts for more 
than 90% of cases.1 
In 2012, there were 369,200 new cases of oral cancer reported worldwide, with two-
thirds of them being diagnosed in developing countries. These tumors were 
responsible for approximately 145,328 deaths worldwide per year. The areas 
characterized by high incidence rates for oral cancer (excluding lip) are found in the 
South and Southeast Asia (e.g. Sri Lanka, India, Pakistan, and Taiwan), parts of 
Western (e.g. France) and Eastern Europe (e.g. Hungary, Slovakia, and Slovenia), 
parts of Latin America and the Caribbean (e.g. Brazil, Uruguay, and Puerto Rico) and 
in Pacific regions (e.g. Papua New Guinea and Melanesia).1 
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Oral cancer is the most common cancer in men in high-risk countries such as Sri 
Lanka, India, Pakistan, and Bangladesh, and contributes up to 25% of all new cases of 
cancer. The 5 year survival rate for patients with early localized disease is 80% and 
that with distant metastases is 19%. The aetiology of oral cancer is multifactorial. The 
most important risk factors being tobacco, excess consumption of alcohol, and betel 
quid usage, factors which act separately and synergistically.2 
Oral epithelial dysplasia (OED) is a common precursor of oral cancer. The occurrence 
of oral squamous cell carcinoma (OSCC) is preceded by visible changes of the oral 
mucosa. Longitudinal studies of rural populations in India have revealed that 80% of 
oral cancers are preceded by precancerous conditions or lesions.3  
The WHO has recently recommended abandoning the distinction between potentially 
malignant lesions and potentially malignant conditions and has coined the term 
potentially malignant disorders. The term ‘oral potentially malignant disorders’ 
(OPMD) was adopted by the WHO in 2005 to describe oral lesions and conditions 
associated with a risk of malignant transformation.4  
In the WHO collaborating workshop conducted in 2007, the disorders of concern 
were leukoplakia, erythroplakia, oral submucous fibrosis, oral lichen planus, palatal 
lesion of reverse smoking of tobacco, discoid lupus erythematosus, and hereditary 
disorders like dyskeratosis congenital and epidermolysis bullosa.5 
Oral leukoplakia (OL) is defined as a predominantly white lesion of the oral mucosa 
that cannot be characterized as any other definable lesion.6 In 2007, the WHO 
rephrased the definition as white plaques of questionable risk, (other) known diseases 
and disorders that carry no increased risk of cancers having been excluded.4 
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The WHO has established criteria for dysplasia, including the architectural and 
cytologic changes in the epithelium. The WHO’s criteria for architectural changes in 
the epithelium includes irregular epithelial stratification, loss of polarity of basal cells, 
drop-shaped rete ridges, increased number of mitotic figures, abnormal mitoses not 
limited to basal or parabasal layers, premature keratinization in single cells 
(dyskeratosis), keratin pearls within rete ridges. The criteria for cytologic changes in 
the epithelium include abnormal variation in nuclear size (anisonucleosis), abnormal 
variation in nuclear shape (nuclear pleomorphism), abnormal variation in cell size 
(anisocytosis), abnormal variation in cell shape (cellular pleomorphism), increased 
nuclear–cytoplasmic ratio, increased nuclear size, atypical mitotic figures, increased 
number and size of nucleoli, and hyperchromasia.7  
Grading dysplasia depends on the extent of involvement of the epithelial layers by the 
dysplastic changes. In cases of mild dysplasia, cytologic and architectural changes are 
confined to the lower third of the thickness of the epithelium; in cases of moderate 
dysplasia, changes are seen in up to two-thirds of the thickness of the epithelium. In 
cases of severe dysplasia, the dysplastic changes fill more than two-thirds of the 
thickness, but less than the entire thickness of the epithelium. The dysplastic cells of 
carcinoma-in-situ (CIS) occupy the entire thickness of the epithelium (bottom to top 
changes), although the basement membrane is still intact.8 
Lichen planus (LP) is defined as an inflammatory disease of chronic nature, affecting 
skin and mucous membranes. The prevalence of LP is estimated at 0.22% to 5% 
worldwide, and the incidence of oral lichen planus (OLP) is estimated at up to 2.2%. 
Oral lesions are seen in around 60% of patients with cutaneous LP. However, in 
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patients with predominant OLP, cutaneous lesions develop in only 15% of the 
patients.  
Microscopic features of OLP include hyperparakeratosis, hyperorthokeratosis, and 
combinations of the two; cytoid (Civatte) bodies; basal cell hydropic change; and a 
band-like chiefly lymphocytic infiltrate in the lamina propria. Additional findings 
include saw-tooth rete ridges, atrophy, acanthosis, a homogeneous eosinophilic 
deposit at the epithelium-connective tissue junction, and ulceration. Compared to 
cutaneous disease, oral lesions less often exhibit saw-tooth rete ridges and more 
frequently exhibit atrophy.9 
Oral submucous fibrosis (OSMF) is defined as a chronic insidious disease affecting 
any part of the oral cavity and sometimes pharynx, occasionally preceded and/or 
associated with vesicle formation and always associated with juxtaepithelial 
inflammatory reaction followed by fibroblastic change of the lamina propria with 
epithelial atrophy leading to stiffness of oral mucosa causing trismus and inability to 
eat. The WHO subsequently defined OSMF as a slowly progressive disease in which 
the fibrous bands form in the oral mucosa, ultimately leading to severe restriction of 
movement of the mouth including the tongue.  
In 1956, Paymaster first described the precancerous nature of OSMF. In 1972, 
Pindborg et al. and various groups put forward 5 criteria to prove that OSMF is 
precancerous. Malignant transformation rate of OSMF was found in the range of 7%-
13% depending on the study population.10 
The development of cancer is a multistep process, where accumulation of genetic 
defects, followed by clonal selection and expansion of altered cells, ultimately leads 
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to the development of cancer. Since accumulation of genetic defects can be studied 
only with changes at molecular level prior to the evident appearance of cellular or 
clinical changes, detection of these molecular changes would ideally allow earlier 
diagnosis of high risk states, and therefore help improve prognosis.11 
Increasing evidence indicates that the unique member of the inhibitor of apoptosis 
(IAP) protein family, survivin, is not only an essential protein molecule for the 
regulation of mitosis and apoptotic inhibition but it also plays a role in certain 
physiological processes as well as in pathological conditions such as carcinogenesis in 
many human organs/cells. Eight members of the family of IAPs are reported, 
including X-linked IAP, cIAP1, cIAP2, NAIP (NLR family, apoptosis inhibitory 
protein), livin, ILP2 (IAP-like protein 2), BRUCE and survivin.12 The IAP family 
contains various members that have been shown to inhibit activated caspases.13 
Diffuse expression of survivin has been observed during fetal development but the 
expression in adult tissues is rare or totally absent. Moreover, survivin expression has 
been detected in various human cancers including bladder, colon, liver, brain, lung, 
and prostate. In the majority of cancers studied to date, survivin expression is 
associated with poor prognosis.14 
Survivin is a member of the IAP family, encoded as a 16.3 kilodalton protein 
consisting of 142 amino acids.15 The proteins are characterized by a domain of about 
70 amino acids, termed baculovirus IAPs repeat (BIR). Unlike other IAPs, survivin is 
small and has only a single N-terminal BIR domain, a long C-terminal alpha-helix 
coiled region, and forms a stable dimmer in solution. 
  
It inhibits apoptosis differently than bcl
with caspase-3 and caspase
cell death by interfering with the processing of caspase
the intrinsic pathway of apoptosis.
Gap2 (G2)/Mitosis (M)
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Fig 1: Survivin pathways to apoptosis12 
Fig 2: Structure of Survivin Protein12 
-2 either by directly or indirectly interfering 
-7 function via its BIR domain. Survivin also neutralizes 
-9, the upstream inhibitor in 
16 High expression of survivin was observed in the 
 phase and a rapid decline was noted in Gap
 
 
1 (G1) phase of cell 
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cycle. Positive correlation between survivin expression levels with aggressive disease 
and poor clinical outcome have been established.12 
The various functions of survivin are broadly classified into two categories:  
Mitotic regulation Cell-death inhibition 
Localization to the mitotic apparatus 
Inhibition of extrinsic/intrinsic apoptotic 
pathways 
Catastrophic defect of mitosis in survivin 
–/– embryos 
Resistance to apoptosis in transgenic mice 
Failed cytokinesis and polyploidy 
induced by antisense or dominant-
negative mutants 
Increased sensitivity to apoptosis of 
survivin +/– mice 
Defects in spindle assembly, chromatid 
separation and spindle-checkpoint 
activation after antibody microinjection 
Spontaneous apoptosis induced by 
antisense, 
dominant-negative mutants or ribozyme 
and association with caspases. 
Table 1: Functions of survivin 
Survivin expression was found to be localized mainly in the parakeratin/keratin and 
prickle cell layer of oral leukoplakia cases, with cytoplasmic positivity. Survivin 
expression was found to be weak in well differentiated squamous cell carcinomas 
(WDSCCs), in which the keratinocyte showed weak to moderate cytoplasmic survivin 
expression. All poorly differentiated squamous cell carcinomas (PDSCCs) showed 
moderate to strong survivin expression and distinct nuclear expression of survivin. 
The degree of survivin expression was found to increase with increasing grade of 
malignancy.13 
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Ambrosini et al reported a new human gene encoding a structurally unique IAP 
apoptosis inhibitor which was designated as survivin. They demonstrated that 
survivin, while being undetectable in terminally differentiated adult tissue, was 
prominently expressed in transformed cell lines and in most common forms of human 
cancers of lung, colon, breast, prostrate, and pancreas, in vivo.17 Fortugno et al 
reported that survivin exists in immunochemically distinct subcellular pools 
(cytoplasmic and nuclear).18 Li et al reported that the cytoplasmic survivin played a 
role in cell survival but not in cellular proliferation while nuclear pool of survivin was 
involved in promoting cell proliferation in most cases.19 
Lin et al reported that survivin staining was mainly cytoplasmic; it could be found in 
both oral SCC cells and dysplastic basal and spinous epithelial cells but was rarely 
noted in normal oral epithelial cells.20 In the study by Kim et al, survivin protein was 
detected at varying levels in all OSCC cell lines and clinical samples of OSCC in 
which survivin was predominantly expressed in the proliferating basal cell layer of the 
tumor mass. On the contrary, survivin expression was not observed in normal gingival 
keratinocytes.14 
Observing a high frequency of tumor cells expressing p63 and survivin, Lauxen et al 
highlighted the role of these proteins in the malignant transformation of oral 
epithelium and suggested that p63 and survivin may constitute attractive targets for 
cancer therapy in patients with OSCC.21 No correlation was however found between 
survivin or p53 expression and clinicopathological parameters by Khan at al who 
concluded that overexpression of these two markers suggests their role in early stages 
of oral carcinogenesis. Reporting prognostic significance only for the markers 
survivin and phosphorylated protein kinase strain AK thymoma (pAkt), these authors 
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concluded that these two markers, connected with cell migration, might have utility as 
predictors of long-term outcomes for patients with HNSCC.22 
Pickhard et al reported a correlation between higher cytoplasmic survivin scored and 
high scores of EGFR expression, and further observed an association between nuclear 
survivin expression and poor overall survival rate.23 Li et al concluded that survivin 
might inhibit both synthesis and activation of caspase 3, hence inhibiting cell 
apoptosis and facilitating eventual development of OSCC.24  
Considering this background of survivin’s role in oral carcinogenesis, this study was 
undertaken to correlate the immunohistochemical expression of survivin in oral 
potentially malignant disorders. 
Objectives 
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1. Evaluation of survivin immunoexpression patterns and survivin 
immunoreactivity in OL, OSMF, OLP and NOE. 
2. Comparison of immunoexpression patterns and immunoreactivity of survivin 
between OL, OSMF, OLP and NOE; between OL and OSMF; between OL 
and OLP; and between OSMF and OLP and evaluate the significance of 
survivin as a prognostic marker. 
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Ambrosini et al (1997) reported a new human gene encoding a structurally IAP 
apoptosis inhibitor which was designated as survivin. They demonstrated that 
survivin, while being undetectable in terminally differentiated adult tissue, was 
prominently expressed in transformed cell lines and in most common forms of human 
cancers of lung, colon, breast, prostrate, and pancreas, in vivo.17 
Fengzhi Li et al (1998) reported that a new IAP protein, survivin, was expressed in 
the G2/M phase of the cell-cycle in a cycle-regulated manner. At the beginning of 
mitosis, survivin associates with microtubules of the mitotic spindle in a specific and 
saturable reaction that is regulated by microtubule dynamics. The results indicated 
that survivin may counteract a default induction of apoptosis in G2/M phase.
25 
Ambrosini et al (1998) reported the existence of a potential effector cell protease-
1/survivin gene cluster and identified survivin as a new target for disrupting cell 
viability pathways in cancer. Constitutive or metallothionein induction of effector cell 
peptidase receptor 1, potentially acting as a survivin antisense, down-regulated 
endogenous survivin in transformed cells and resulted in increased apoptosis and 
inhibition of cell proliferation.26 
Jiang et al (2001) examined the distribution of endogenous levels of survivin in both 
untreated and Taxol-treated HeLa (Henrietta Lacks) cells, as well as in other tumor-
derived and normal cell lines derived from different tissues and reported that during 
interphase, endogenous survivin in untreated HeLa cells was reproducibly observed 
localized closely with a pair of tubulin foci on the centrosomes, establishing the role 
of survivin in mitosis and apoptosis.27 
REVIEW OF LITERATURE 
 
12 
 
Frost et al (2002) evaluated the survivin expression in 73 cervical squamous tissue 
samples that included 31 normal, 17 low- and 15 high grade squamous intraepithelial 
lesions and 10 SCCs. Survivin was detected in 22 (71%) of 31 sections of benign 
cervical squamous mucosa, in 14 (82%) of 17 sections of low grade intraepithelial 
lesions, in 9 (60%) of 15 sections of high grade intraepithelial lesions, and in 4 (40%) 
of 10 sections of SCCs. While the nuclear areas of normal cervical mucosa was 
stained with survivin and cells in the basal layer showed no staining for survivin, 
staining in other pathological lesions showed cytoplasmic staining predominantly.28 
Lo Muzio et al (2003) evaluated the survivin expression in 110 samples of paraffined 
and 10 frozen specimens of primary OSCC, 7 paraffined specimens of lymph node 
(6 cases) and tissue metastases (1 case) of OSCC. Immunohistochemical staining for 
survivin was observed in 20– 100% of cancer cells. While the neighboring normal 
tissues did not express survivin, about 91 cases (82.7%) of oral mucosa cancers 
positively expressed survivin. Patients with low survivin expression had better 
survival rates than the group with medium to high survivin expression. It was 
concluded that survivin expression may identify cases of oral SCC with more 
aggressive and invasive phenotype.29 
Lo Muzio et al (2003) evaluated the expression of survivin in 51 samples of which 16 
were oral epithelial dysplasias that progressed to invasive OSCCs, 30 cases of oral 
epithelial dysplasias that did not evolve into OSCC and 5 cases from normal oral 
mucosa (NOM). Survivin staining was sporadic and weak in the basal and parabasal 
layers in normal mucosal specimens, detectable in 10 of 30 cases (33%) of 
precancerous lesions that did not progress to OSCC, 15 of 16 cases (94%) of 
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precancerous lesions that progressed to OSCC and in 16 of 16 cases (100%) of OSCC 
specimen.30 
Tanaka et al (2003) evaluated survivin expression in 71 patients of OSCC and 38 
cases of OL with NOM as control. All NOM specimen showed absence or significant 
down regulation of survivin expression. Among the tumors examined, 41 cases (58%) 
revealed survivin immunoreaction in the cytoplasm of tumor cells. Fourteen (14) of 
the 38 OLs (37%) were considered survivin positive. Overall, 37% of the evaluated 
premalignant lesions showed survivin expression.31 
Lo Muzio et al (2003) analyzed the survivin expression in 47 samples that included 
11 OSCC, 16 OL, and 20 normal oral epithelial (NOE) specimens. Human Papilloma 
Virus (HPV) positive precancerous lesions and HPV negative OSCCs demonstrated 
higher levels of survivin, concluding that HPV may have a direct or indirect effect on 
the regulation of the survivin expression level in oral premalignant and malignant 
diseases.32 
Smith et al (2003) performed a systematic review of biomarkers of dysplasia in the 
oral cavity and reported that the presence of loss of heterozygosity or allelic 
imbalance at specific loci, survivin and matrix metalloproteinase-9 positivity, and 
non-diploid deoxyribonucleic acid (DNA) content increase the risk of progression 
from dysplasia to oral cancer.33 
Sharma et al (2004) evaluated the anti-apoptotic protein expression in 50 cases of 
HNSCC and in 19 histopathologically normal tissues and reported that B Cell 
Lymphoma 2 (Bcl-2), BCL Extra large (Bcl-XL), and survivin were upregulated in 
tumor tissues in comparison to normal tissues. Expression of Bcl-2 and survivin was 
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significantly associated with loss of differentiation in tumors and Bcl-XL with nodal 
metastasis.34 
Li et al (2005) reported that survivin exists in 2 subcellular pools (cytoplasmic and 
nuclear) which were consistent with its function in the regulation of both cell viability 
and cell division. The cytoplasmic survivin played a role in cell survival but not in 
cellular proliferation while nuclear pool of survivin was involved in promoting cell 
proliferation in most cases. Survivin had a number of splicing variants, differing in 
their subcellular localization and functions with respect to cell survival and cell 
division.19 
Kim et al (2005) evaluated 281 lymph nodes in 97 patients out of 113 patients with 
OSCC and reported that lymph node cytokeratin and survivin messenger ribonucleic 
acid (mRNA) expression had significant effects on OSCC survival rates. They 
reported that the survivin positive group had a 2.5 times greater OSCC risk than the 
negative group.35 
Lo Muzio et al (2005) evaluated 78 cases of OSCC and reported that survivin 
expression, stage and grade of differentiation are significant to survival and survivin 
expression may identify cases of OSCC with more aggressive and invasive 
phenotype.36 
Lin et al (2005) evaluated survivin expression in 62 cases of epithelial dysplasia and 
92 cases of OSCC. Cytoplasmic survivin staining was positive in 97% of epithelial 
dysplasia cases and in 98% of OSCC cases but there was no evidence of staining in 
adjacent NOM. They reported that survivin expression is a common feature of 
OPMD.20 
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Freir et al (2006) studied the immunohistochemical expression of survivin in 
251 OSCC tissue sections. High survivin expression was found in 67.3% (169/251) of 
cases and showed decreased overall survival of patients. They concluded that survivin 
might be used as a stratification marker to define OSCC patients, who would 
potentially benefit from radiotherapy.37  
Jane et al (2006) evaluated the expression of survivin, Bcl-2, and Bcl associated X 
(Bax) in 38 patients of OSCC and 17 patients of OL and reported that the expression 
of survivin, Bcl-2, and Bax was found to increase with increased grades of 
malignancy. Increase in the expression of survivin was statistically more significant.13  
Fukuda et al (2006) reported that using molecular dissection of genes associated with 
aberrant proliferation of cancer cells and endothelial cells have identified survivin as a 
candidate gene responsible for cancer progression and vascular disease and as an 
attractive molecular therapeutic target for management of oral cancer and oral 
premalignant conditions.38 
Pannone et al (2007) evaluated the survivin expression and M-phase promoting 
factor (MPF) in 32 OSCCs and 17 dysplasias from areas adjacent to OSCC. Survivin 
and p-34cdc2 expression was positive in all cases of OSCC while cyclinB1 was 
positive in only 80% of cases. All OPLs associated with OSCC expressed survivin 
and p-34cdc2 while cyclin B1 was positive in only 70% of cases. It was concluded 
that MPF and survivin are expressed during early and late phase of oral 
carcinogenesis.39 
Knauer et al (2007) demonstrated that nuclear export is essential for the biological 
activity of survivin and promote the identification of molecular decoys to specifically 
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interfere with survivin’s nuclear export as potential anticancer therapeutics via a 
newly identified evolutionary conserved Crm1-dependent nuclear export signal (NES) 
in survivin, thereby confirming an active role of survivin-specific transport inhibitors 
in anticancer therapeutics.40 
Preuss et al (2008) evaluated survivin expression in formalin-fixed, paraffin 
embedded (FFPE) tissue from 106 patients histologically confirmed SCC of the 
oropharynx. While nuclear expression of survivin was found in 19% of the tumours, 
cytoplasmic expression was evident in 58% of the cases. This study showed that 
nuclear accumulation of survivin correlates with HPV-independent carcinogenesis 
and was an independent predictor of poor survival in patients with OSCC.41 
Zhou et al (2008) evaluated 82 patients with OSMF and OSCC and demonstrated that 
20 of the 40 OSMF cases (50%) showed phosphorylation of survivin threonine 34 and 
reported that protein phosphorylation is the most important post translational 
modification that is implemented in the regulation of cell proliferation, differentiation, 
apoptosis, cytoprotection and cell cycle transitions. They suggested a key role for 
survivin Thr34 phosphorylation in tumor development and therapy resistance.42 
Khan et at (2008) evaluated 45 patients (29 OSCC and 16 oral premalignant lesions) 
of which 9 cases were OL, 2 were OSMF, and 2 were erythroplakia and reported that 
21 of 29 (72%) OSCC patients and 7 of 16 (44%) patients with oral premalignant 
conditions were survivin positive while NOM specimens did not demonstrate survivin 
expression. They reported that the overexpression of survivin and p53 in premalignant 
lesions suggest a role in early carcinogenesis.43 
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Oluawadara et al (2009) evaluated 14 cases of OLP, 6 cases of chronic interface 
mucositis, 4 cases of epithelial dysplasia and 27 cases of OSCC and reported that 
survivin expression was observed in 64.3% of OLP cases, 50% in cases of chronic 
interface mucositis, 100% in cases of oral epithelial dysplasia and 96.3% in cases of 
OSCC. They also suggested that Lck-PI3K/Akt-survivin molecular loop may play an 
important role in the spectrum of chronic inflammation, autoimmunity, and cancer 
transformation in OLP.44 
Chaiyarit et al (2009) evaluated the immunohistochemical expression of survivin and 
heat shock protein 90 in formalin fixed paraffin embedded archival blocks of 29 OLP 
cases and 29 NOM specimens. Basal and suprabasal epithelial cells were positive for 
survivin in NOM. There were 5 cases with 25% to <50% positively stained epithelial 
cells, 14 cases with 50% to <75% immunostaining and 10 cases were with >75% 
immunostaining for survivin. Basal and suprabasal epithelial cells were positive for 
survivin in OLP cases. Infiltrating mononuclear cells in the lamina propria of OLP 
lesions were positive for survivin. There was one case with no immunostaining, 
7 cases with <25% immunostaining, 9 cases with 25% to <50% immunostaining, 
8 cases with 50% to <75% immunostaining; and 4 cases were with >75% 
immunostaining. Significant differences of survivin expression between NOM and 
OLP were demonstrated.45 
Lodi et al (2010) measured the mRNA levels by real time polymerase chain reaction 
method in 15 specimens of normal mucosa, 17 from oral premalignant lesions and 17 
from OSCC. All samples of NOM showed survivin expression but samples from 
premalignant lesions had higher median survivin expression and the highest survivin 
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expression was noted in the OSCC group. The authors reported a significant statistical 
difference between the 3 groups.46 
Zhou et al9 (2010) evaluated survivin expression in 15 NOE specimens, 50 cases of 
OSMF which were newly diagnosed without OSCC and 52 OSCC transformed from 
OSMF. Survivin expression was localized mainly in the basal/parabasal and prickle 
cell layers in samples of OSMF. About 24 out of 50 OSMF cases (48%) showed 
cytoplasmic survivin positivity. Two (2) out of 10 early stage (20%) and 9 out of 20 
moderately advanced stage (45%) of OSMF were found to exhibit weak survivin 
expression. Moderate cytoplasmic survivin expression was evident in 65% of the 
advanced stage OSMF cases. The important role played by survivin during the 
malignant transformation of OSMF was analyzed and it may provide an indication to 
early prevention and diagnosis in the progression of OSMF.15 
Li et al (2012) estimated survivin immunoexpression using enzyme linked 
immunosorbent assay (ELISA) in 13 OSCC and 13 peritumoral samples of OSCC and 
10 NOM samples. Upon analysis of survivin expression using ELISA, tumor tissue 
showed significantly higher level of survivin expression than in peritumoral tissue, 
while survivin in normal tissue from tumor-free patients was significantly lower than 
tumor and peritumoral tissue. It was concluded that survivin may inhibit cell 
apoptosis and facilitating eventual development of OSCC.24 
Santarelli et al (2013) analyzed survivin expression in 55 saliva samples OSCC 
patients and 30 samples from healthy controls, using enzyme immunometric assay. 
Positive survivin expression was noted in the saliva of 35 of 55 (63.6%) OSCC 
patients, while 12 of 30 (40%) samples were positive for survivin among the control 
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group. Salivary survivin proves to be an interesting biomarker for OSCC, but its use 
as a single marker may be not sufficient for the early diagnosis of OSCC.47 
Negi et al (2015) studied immunohistochemical expression of survivin in 45 
specimens of FFPE tissue blocks, 15 in each of NOE, OL, and OSCC. Survivin 
positivity was demonstrated in 20% of normal mucosa cases, 53.33% cases of OL, 
and 80% OSCC. In cases of OED and SCC, a significantly high incidence of survivin 
expression was found which may be an early event in initiation and progression of 
OSCC.48  
Mishra et al (2015) evaluated expression of six survivin isoforms in 4 oral cancer cell 
lines (AW8507, AW13516, UPCI-SCC040, and UPCI-SCC029B), a dysplastic oral 
cell line, 75 paired oral tumor and adjacent normal tissues and 12 NOM tissues from 
healthy individuals by real time polymerase chain reaction (PCR). A significant 
predominant expression of survivin was observed in all the cell lines in comparison to 
the minor isoforms of survivin (p<0.05). In comparison to normal tissues from 
healthy individuals, 88% oral cancer cases showed overexpression of survivin wt 
while survivin ∆Ex3 was upregulated in 64% cases. Survivin 3B and survivin 2B 
showed overexpression in 33% and 76% cases respectively. Overexpression of 
survivin 2α was observed in 41% cases and survivin 3α in 50% cases. The study 
indicated that oral cancers overexpress the antiapoptotic survivin variants, which 
exhibit an association with advanced tumor stage, implying a role for these variants in 
oral tumorigenesis.49 
Suganya et al (2016) evaluated 70 neutral-buffered, FFPE biopsy specimens and 
grouped them into 3 classes: Group 1 (control) – 10 cases of NOM, Group 2 – 50 
cases of OLP confirmed histopathologically and Group 3 – 10 cases of OSCC 
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(positive control). Higher mean positive cells for survivin were recorded in the OSCC 
group (28.43 mean positive cells), followed by OLP group (16.65 mean positive 
cells), and NOE group (2.25% mean positive cells). Survivin expression was seen in 
95% cases of OLP which was mainly of moderate intensity (46%), followed by mild 
intensity in 44% of cases.50 
Gayathri et al (2017) studied the survivin expression in neutral-buffered, FFPE 
specimens of 30 patients each with OL and OSCC. Expression of survivin was noted 
in all grades of dysplasia and OSCC and was significant when compared with 
different degrees of dysplasia and histopathological grades of OSCC. The high 
expression of survivin was proposed to be related to malignant transformation in OL 
and poor prognosis in OSCC.51 
Kulkarni et al (2017) evaluated survivin expression in 43 cases of WDSCC, 
moderately differentiated squamous cell carcinoma (MDSCC), and PDSCC. PDSCCs 
demonstrated significantly high survivin expression compared to WDSCC & MDSCC 
(p< 0.01). An increase in the level of survivin expression was noted in OSCC 
compared to the controls but the use of survivin as a single marker may be not 
sufficient for the early diagnosis of OSCC.52 
Li et al (2017) evaluated 45 cases of FFPE tissue specimens including 16 cases of OL 
with low-moderate epithelial dysplasia, 12 cases of OL with severe epithelial 
dysplasia, and 17 cases of W/MDSCC. The expression of survivin was gradually 
increased (normal < OL with low-moderate dysplasia < OL with severe dysplasia < 
OSCC) during the progression from abnormal cell proliferation to malignant 
transformation.53 
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Deo et al (2017) evaluated survivin immunoexpression in 10 FFPE samples each of 
dysplasia, WDSCC, MDSCC, and PDSCC. Of the 10 cases of dysplasia, variable 
survivin expression was noted in all cases. Both focal nuclear and cytoplasmic 
staining was observed. Of the 10 cases of dysplasia, 7 cases showed less than 5% of 
survivin expression, 2 cases showed 5-25% of survivin expression, and 1 case showed 
51–75% of survivin expression. Intergroup comparison revealed a statistical 
significance between dysplasia and MDSCC.54 
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Prior to the commencement of the study, ethical approval was obtained from the 
institutional review board of Best dental science college, Madurai, (Annexure I). 
Appropriate permissions were obtained from Meenakshi Mission Hospital and 
Research Centre, Madurai to carry out the immunohistochemistry (IHC) procedures. 
SOURCE OF DATA: 
This retrospective study was done by retrieving FFPE tissue specimens of OL, OSMF, 
and OLP from the archives and fresh specimens of NOE in Department of Oral 
Pathology and Microbiology, Best Dental Science College and Hospital, Madurai. 
 STUDY SAMPLE SIZE: 
The study material comprised of 60 FFPE tissue specimens  
1. 15 histopathologically confirmed tissue specimens of OL.  
2. 15 histopathologically confirmed tissue specimens of OSMF. 
3. 15 histopathologically confirmed tissue specimens of OLP. 
4. 15 histopathologically confirmed tissue specimens of NOE. 
 STUDY SAMPLE GROUP:  
The study comprised of 4 groups: 
Group I (Cases) 
Fifteen (n=15) archival blocks of histopathologically confirmed tissue specimens of 
OL. 
Group II (Cases) 
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Fifteen (n=15) archival blocks of histopathologically confirmed tissue specimens of 
OSMF. 
Group III (Cases) 
Fifteen (n=15) archival blocks of histopathologically confirmed tissue specimens of 
OLP. 
Group IV (Controls) 
Fifteen (n=15) fresh samples of NOE. 
INCLUSION CRITERIA: 
Histopathologically confirmed diagnosis of 
1.  OL – histopathologically confirmed cases of epithelial dysplasia including 
CIS 
2. OSMF – Different stages of the lesion 
3. OLP 
4. NOE – derived from fresh samples from department of periodontics 
EXCLUSION CRITERIA: 
1. Cases of oral squamous cell carcinoma 
2. Cases of lichenoid reactions 
3. Insufficient case reports. 
4. Insufficient tissue samples. 
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CHEMICAL REAGENTS USED: 
1. Primary antibody - 6 milliliter (mL) (Rabbit monoclonal antibody survivin, 
Path in situ®) (Fig 3). 
2. Secondary antibody (Biogenex Super sensitive Detection system) (Fig 4). 
3. Tertiary antibody (Biogenex Super sensitive Detection system) (Fig 5). 
4. 3,3'-Diaminobenzidine (DAB) chromogen (Biogenex Super sensitive 
Detection system) (Fig 6). 
5. Methanol (Fischer Scientific India Pvt Ltd). 
6. Anhydrous citric acid (Merck Specialties Pvt Ltd). 
7. Trisodium citrate dihydrate (Merck Specialties Pvt Ltd) (Fig 7). 
8. Xylene (Fischer Scientific India Pvt Ltd). 
9. Absolute alcohol (Jiangsu Huaxi International Trade Co Ltd, China). 
10. Sodium hydroxide (NaOH, Rankem Lab reagent, India). 
11. Sodium chloride (NaCl, Qualikems fine chemicals, India). 
12. Tris buffer (Fischer scientific India Pvt Ltd (Fig 8). 
13. Hydrochloric acid (HCl, Qualikems fine chemicals, India). 
14. 30% Hydrogen Peroxide (H2O2). 
15. Hematoxylin (Merck specialties Pvt Ltd). 
16. Distyrene Plasticizer Xylene (DPX, Fischer Scientific India Pvt Ltd). 
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Fig 3: Primary antibody 
Fig 4: Secondary antibody 
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Fig 5: Tertiary antibody 
Fig 6: DAB Chromogen 
 
 
 
  
Fig 8: Chemicals for preparation of Tris Buffer Saline (TBS)
 
Fig 7
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: Chemicals for preparation of citrate buffer
 
 
 
 
MATERIALS AND METHODS 
 
28 
 
EQUIPMENTS USED: 
1. Magnetic stirrer (Scientific instruments Pvt Ltd) (Fig 9). 
2. Electronic weighing machine (Citizen, Wensen Pvt Ltd) (Fig 10). 
3. Potential of Hydrogen (pH) meter (Hanna instruments, Mauritius) (Fig 11). 
4. Microwave oven (Fig 12). 
5. Fine tissue paper. 
6. Slide rack. 
7. Borosil jars. 
8. Measuring cylinder 
9. Fully automated microtome (Leica RM2125RT) (Fig no.13) 
10. Slide truft. 
11. Polylysine coated slides. 
12. Moist chamber. 
13. Forceps. 
14. Micropipettes (10-100/5-10 microliter) (Perfect micropipettes, India). 
15. Refrigerator. 
16. Light microscope (Olympus BX53®) (Fig no.14). 
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Fig 9: Magnetic stirrer 
Fig 10: Weighing machine 
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Fig 11: pH meter 
Fig 12 : Microwave oven 
 
 
  
Fig no 14: Olympus BX53 Light microscope and photomicrography done with 
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Fig no.13: Fully automated microtome 
Prog Res Speed XT Core 3. 
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METHODOLOGY 
Prior to commencement of the IHC staining procedure, citrate buffer and Tris Buffer 
Saline (TBS) were prepared. 
Preparation of citrate buffer [pH 6.0, 1 liter (L)] 
1. Weigh 0.18 gram (g) anhydrous citric acid. 
2. Weigh and add 2.1 g sodium citrate. 
3. Add 4-8 drops of NaOH. 
4. Add distilled water in measuring cylinder up to 1000 mL. 
5. Mix well by magnetic stirrer. 
6. Control pH by NaOH/HCl. 
Preparation of TBS (pH 7.4 to 7.6, 2 L) 
1. Weigh NaCl 17.2 g. 
2. Weigh and add tris buffer 12.0 g. 
3. Add 7.0 mL of 1 normality (N) HCl (To make 1N HCl, take 37 mL HCl and 
distilled water up to 1 L). 
4. Add distilled water up to 1000 mL and mix well by magnetic stirrer. 
5. Control pH by adding drop by drop 1N HCl. 
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IMMUNOHISTOCHEMICAL STAINING PROCEDURE 
From the clinically and histopathologically confirmed FFPE blocks, sections that 
were 4 microns thick were cut and stained with routine Hematoxylin and Eosin 
staining. The histological features of OL, OSMF, and OLP were analyzed under light 
microscopy. Cases that met the histologic criteria of OL, OSMF, and OLP were 
selected for the immunohistochemical analysis. Later these selected slides were 
subjected to IHC procedure. IHC procedures were carried out in Meenakshi Mission 
Hospital and Research Centre, Madurai, as per the step-by-step procedure described 
below: 
STEP 1: COATING OF SLIDES 
Take thin section of tissues on polylysine-coated slides, one day prior to the IHC 
staining procedure. 
STEP 2: DEPARAFFINISATION AND REHYDRATION OF TISSUE 
1. Xylene, two changes [5 minute (min) each, at room temperature]. 
2. Acetone, one change (3 min). 
3. Absolute alcohol (3 min). 
4. Running tap water (15 min). 
5. Leave the section in water until the next step. 
STEP 3: ANTIGEN RETRIEVAL 
1. Put the slides with the truft in the citrate buffer jar. 
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2. Microwave it at high power for 30 min or 15 min high power and 10 min low 
power. 
3. Bring the solution at room temperature. 
4. Discard the citrate buffer. 
5. One wash by TBS. 
STEP 4: ENDOGENOUS PEROXIDISE BLOCKAGE 
1. Make 4% H2O2 (96 mL methanol + 4 mL 30% H2O2). 
2. Put the slides in truft and leave in 4% H202 for 30 min at room temperature. 
3. TBS wash (3 changes) 5 min each. 
STEP 5: PRIMARY ANTIBODY 
1. Take out the slides from the truft one by one. 
2. Wipe off the excess liquid by fine tissue paper. 
3. Mark the tissues by wax pens. 
4. Put the slide in moist chamber. 
5. Apply one drop of primary antibody to each section. 
6. Incubate at room temperature for 1 hour. 
7. 3 changes of TBS (5 min each). 
STEP 6: SECONDARY ANTIBODY 
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1. Wipe off the excess liquid. 
2. Put the slides in moist chamber and apply secondary antibody. 
3. Incubate at room temperature for 30 min. 
4. 3 changes of TBS (5 min each). 
 STEP 7: LINK ANTIBODY/TERTIARY ANTIBODY 
1. Wipe off the excess liquid. 
2. Add link antibody and incubate at room temperature for 30 min. 
3. 3 changes of TBS (5 min each) and keep the slides in TBS. 
STEP 8: DAB CHROMOGEN 
1. Wipe off excess liquid. 
2. Apply the DAB chromogen. 
3. See under the microscope for colour. 
4. If satisfactory staining, remove the DAB. 
5. Immerse in distilled water to stop the reaction. 
STEP 9: COUNTER STAINING (HEMATOXYLIN) 
1. Make 1 to 3 dips in hematoxylin for counter staining. 
2. Wash under running water. 
STEP 10: DEHYDRATION OF TISSUE AND MOUNTING 
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1. Absolute alcohol (1 change). 
2. Acetone (1 change). 
3. Xylene (2 changes). 
4. Take out the slides from xylene and mount. 
EVALUATION METHODS: 
All the slides were viewed using an Olympus® BX53 light microscope and compared 
with their respective Hematoxylin and Eosin sections. Photomicrography of the IHC 
stained slides were done with ProgRes Speed XT Core 3® (Fig 14). To minimize the 
errors while interpretation, two observers examined the IHC stained slides by means 
of light microscope. All the immunohistochemically stained slides from the study 
groups I, II, III, and IV were evaluated for the expression of survivin. Survivin 
immunopositivity was assessed by the presence of a brown colour immunostaining of 
the nucleus and cytoplasm. 
Evaluation of survivin immunoexpression patterns 
The pattern of survivin expression in all the groups was recorded based on their 
localization as cytoplasmic, nuclear, and both cytoplasmic and nuclear expression. 
The intensity of staining was estimated based on the criteria followed by Tanaka 
et al31 and Muzio et al 20:  
 Score 0 : No staining 
 Score 1 : Mild staining intensity 
 Score 2 : Moderate staining intensity 
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 Score 3 : Strong staining intensity 
The percentage of survivin immunopositivity was categorized based on the 
criteria adopted by Tanaka et al31 and Muzio et al 20: 
The percentage of survivin immunopositive cells was estimated and graded, in five 
random fields, on a scale of 0-4 as follows: 
 0 points: No immunopositive cells 
 1 points: <10% immunopositive cells 
 2 points: 10% to 29% immunopositive cells 
 3 points: 30% to 59% immunopositive cells 
 4 points: 60% to 100% immunopositive cells 
Evaluation of survivin immunoreactivity  
The immunoreactivity of survivin in all the groups was assessed semi-quantitatively 
by calculating the immunoreactive score (IRS) as follows: 
IRS = Percentage of immunopositive cells (A) x Intensity of immunostaining (B) 
The IRS score was translated into survivin immunoreactivity as follows 
 0-1: Negative 
 2-3: Mild 
 4-8: Moderate 
 9-12: Strongly positive 
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STATISTICAL ANALYSIS:  
All the relevant clinical, histopathological and immunohistochemical data were 
entered in Microsoft excel. Data analysis was done with the help of computer and 
subjected to appropriate statistical analysis using Statistical Package for Social 
Sciences (SPSS Inc., Chicago, IL, version 22.0 for Windows).   
Using this software, frequencies and percentages were calculated for qualitative 
variables. Chi Square Test was employed to evaluate the gender distribution among 
different study groups (OL, OSMF, OLP and NOE). Fisher’s Chi square test was 
opted to compare the variance in distribution, intensity of staining, percentage of 
immunopositivity and assess pair wise comparison between the groups namely, OL 
and OSMF, OL and OLP, and OSMF and OLP. A 'p' value less than 0.05 denotes 
significant relationship. (p> 0.05 – not significant, p<0.05 – significant, p<0.01 – 
highly significant, p<0.001 – very highly significant). 
Results 
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Clinical characteristics of the study sample 
The study group comprised of 60 cases which includes 15 samples of OL, 15 samples 
of OSMF, 15 samples of OLP, and 15 samples of NOE. The mean age of the patients 
included in the study was 43 years and ranged from 23 to 67 years. Majority of these 
cases were from buccal mucosa (n=47, 78%). Other samples were derived from 
gingiva (n=17, 28.3%), lip (n=1, 1.7%) and tongue (n=1, 1.7%). The clinical 
characteristics of the pathological conditions included in the analysis are presented in 
Table 2. 
All the samples (100%) of OL were obtained from men. The patient’s mean age was 
48.5 years and ranged from 32 to 67 years. Majority of these cases were from buccal 
mucosa (n=12, 80%). Other sites reported were gingiva (n=2. 13.3%) and lip (n=1, 
6.7%). 
Of the 15 OSMF, 8 samples (53.3%) were from males and 7 (46.7%) from females. 
The mean age of these patients was 48.2 years ranging from 27 to 65 years. All the 
samples (100%) were obtained from buccal mucosa. 
For the OLP study group, 6 (40%) males and 9 (60%) females with a mean age of 
39.9 years ranging from 24 to 56 years were selected. Fourteen (14) samples (93.3%) 
were obtained from buccal mucosa while a single sample (6.7%) was from tongue. 
The NOE control group includes 7 (46.7%) males and 8 (53.3%) females with a mean 
age of 35.2 years ranging from 23 to 52 years. All samples (100%) were obtained 
from the gingiva. 
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Comparison of IRS among OL, OSMF, OLP and NOE 
Table 3A-B/Graph 1 compares IRS among OL, OSMF, OLP, and NOE. Moderate 
immunoreactivity was seen in maximum number of samples. The NOE was 
completely negative for survivin. The immunoreactivity ranged from mild (40%) to 
moderate (40%) for OL. In case of OSMF, 40% showed negative immunoreactivity, 
while the remaining samples showed mild (20%) to moderate (40%) expression. The 
majority of OLP samples showed moderate immunoreactivity (80%), though 13.3% 
of them were negative. Strong immunoreactivity was seen in 2 samples (3.3%) which 
include 1 case each of OL and OLP. Statistically high significant difference was 
found among all the 5 groups (P=0.01). 
Pair wise comparison of IRS between OL and OSMF showed that the 
immunoreactivity for survivin was comparatively more for OL with most cases 
showing mild (40%) to moderate (40%) expression, along with strong expression in a 
single case (6.7%). While the IRS for OSMF was moderate in 40% cases with the rest 
showing negative (40%) to mild (20%) expression. There was no statistically 
significant difference between the two groups (p = 0.261).  
Comparison of IRS between OL and OLP revealed a higher value for OLP with about 
80% samples exhibiting moderate immunoreactivity, whereas OL showed mild (40%) 
to moderate (40%) reaction for survivin. A statistically significant difference was 
noted between OL and OLP (p = 0.05). Similarly, when OLP was compared with 
OSMF, a considerably higher immunoreactivity was observed for OLP with around 
80% samples demonstrating moderate expression. On the other hand, OSMF had 
moderate score for only 40% of cases along with mild (20%) to negative (40%) 
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immunoreaction. This difference in IRS between OSMF and OLP was also found to 
be statistically significant (p = 0.05). 
Comparison of intracellular stain location in epithelial cells among OL, OSMF, 
OLP and NOE 
Table 4A-B/Graph 2 compares the intracellular stain location among OL, OSMF, 
OLP, and NOE. The NOE showed absence of survivin expression however a 
negligible amount of cells had nuclear expression in few cases. Nuclear staining for 
survivin was noted in most of the study groups among which OSMF had maximum 
nuclear positivity (86.7%). Both Cytoplasmic and nuclear expression was found in 
only few cases of OL (6.7%), OSMF (13.3%) and OLP (20%). Cytoplasmic 
expression was found in the least number of samples, OL (20%) and OLP (13.3%). A 
highly significant difference was found statistically among all the 4 groups (P=0.001). 
Comparison of intracellular survivin expression patterns between OL and OSMF 
demonstrated a stronger nuclear expression for OSMF (86.7%) along with both 
nuclear and cytoplasmic expression in 13.3% samples. Although majority of OL 
samples exhibited nuclear positivity (73.3%); some cases had expression only in the 
cytoplasm (20%).  However, this difference did not show any significance statistically 
(P=0.173). Likewise, comparison between OL and OLP also did not produce any 
significant difference (P=0.535). Both the study groups exhibited nuclear positivity in 
most cases [OL (73.3%; OLP (66.7%)] with relatively small number of samples 
showing cytoplasmic [OL (20%); OLP (13.3%)] and nuclear – cytoplasmic 
expression [OL (6.7%); OLP (20%)].  
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When the intracellular survivin expression patterns were compared for OSMF and 
OLP, it was noted that nuclear positivity was higher for OSMF (86.7%) compared to 
OLP (66.7%). Cytoplasmic expression was seen only in OLP (13.3%) but both 
cytoplasmic and nuclear expression was found in OSMF (13.3%) and OLP (20%). 
However, there was no statistically significant difference between the two groups 
(P=0.273). 
Comparison of survivin distribution in the epithelium among OL, OSMF, OLP 
and NOE  
Table 5A-B/Graph 3 compares distribution of survivin in the epithelium of OL, 
OSMF, OLP, and NOE. Survivin expression was not seen in most samples (86.7%) of 
NOE, however, there was mild expression in the basal cells of few samples (13.3%). 
Overall, it was expressed predominantly in the basal and parabasal layers in all the 
study samples [OL (60%); OSMF (86.7%) and OLP (100%)]. Nevertheless, it was 
found only in the basal layer of the epithelium in some cases of OL (33.3%) and 
OSMF (13.3%). Statistical significance across the groups was confirmed to be highly 
significant (p = 0.01). 
Comparison of survivin expression across the layers of epithelium between OL and 
OSMF showed that it was expressed mainly in the basal and parabasal layers of 
OSMF (86.7%) compared to OL (60%). The expression of this immunomarker was 
prominent only in the basal cells of OL in almost 33.3% samples while it was found 
in only 13.3% of OSMF. However, there was no significant difference between the 
two groups (P = 0.22). Likewise, comparison of OL with OLP revealed that the 
marker was distributed predominantly in the basal and parabasal layers of OLP 
(100%) which was significantly greater than OL (60%)  (P=0.02). On the other hand, 
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when OSMF was compared with OLP, there was no significant difference in their 
distribution pattern (p = 0.14). Both the study groups exhibited immunoexpression 
chiefly in the basal and parabasal layers [OSMF (86.7%); OLP (100%)]. 
Comparison of percentage of immunopositive cells among OL, OSMF, OLP and 
NOE 
Table 6A-B/Graph 4 compares the percentage of survivin immunopositive cells 
across OL, OSMF, OLP, and NOE. Majority of NOE samples (86.7%) were negative 
for survivin, though relatively few cells (<10%) showed mild survivin expression in 
13.3% of these samples. OL had immunopositivity in the range of <10% (46.7%) and 
10-29% (46.7%) but a single case (6.7%) demonstrated greater positivity 30-59%.  
Most cases (53.3%) of OSMF had expression in only <10% cells and the rest 46.7% 
cases had survivin expression in 10-29% of epithelial cells. The number of 
immunopositive cells was higher for OLP with 80% samples exhibiting reaction in 10 
-29% cells. Statistically, highly significant difference was noted among all the 4 
groups (p = 0.01). 
Comparison of percentage of immunopositive cells between OL and OSMF did not 
show any significant differences (p = 0.22). However, there was a significant 
difference in the number of immunopositive cells between OSMF and OLP with the 
latter showing greater expression (P = 0.05). In spite of having greater percentage of 
survivin expression in OSMF, there was no statistically significant difference with OL 
(P = 0.13). 
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Comparison of staining intensity among OL, OSMF, OLP and NOE 
Table 7A-B/Graph 5 compares the intensity of survivin staining in OL, OSMF, OLP, 
and NOE. Mild expression of survivin was seen in few basal cells of NOE in 13.3% 
samples, even though majority of these tissues (86.7%) showed complete negativity. 
OL expressed survivin strongly in most cases (46.7%) followed by moderate intensity 
(33.3%). The samples of OSMF displayed mild (46.7%) to moderate intensity (40%), 
while a moderate (60%) to strong intensity (26.7%) was observed in OLP. 
Statistically, highly significant difference was noted between all the 4 groups 
(p = 0.01). Intergroup comparison among the study samples did not yield any 
statistically significant difference. 
Summary of intra- and intergroup analysis of the study samples 
Based on the statistical analysis, high significance for survivin expression was noted 
between the OPMD and the NOE in all five categories. However, there was no 
significant difference between OL, OSMF and OLP in intracellular stain location and 
intensity. Significant difference was noted between the groups for IRS, layered 
distribution of survivin expression and mean immunopositivity. The intergroup 
comparison and outcome of the analysis between the study groups is summarized in 
Table 8. 
Key: "p" is level of significance, (p> 0.05 - Not significant; p <0.05 – Significant; p 
<0.01 - Highly significant; p <0.001 - Very highly significant). 
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Table 2 
Clinical characteristics of each pathological condition included in the analysis 
Category 
OL OSMF OLP NOE 
n % n % n % N % 
Sex 
Male 15 100% 8 53.3% 6 40% 7 46.7% 
Female 0 0% 7 46.7% 9 60% 8 53.3% 
Age 
20-40 4 26.7% 5 33.3% 8 53.3% 10 66.7% 
41-60 9 60% 8 53.3% 7 46.7% 5 33.3% 
61-80 2 13.3% 2 13.3% 0 0 0 0 
Site 
Buccal 
mucosa 
12 80% 15 100% 14 93.3% 0 0 
Gingiva 2 13.3% 0 0 0 0 15 100% 
Lip 1 6.7% 0 0 0 0 0 0 
Tongue 0 0 0 0 1 6.7% 0 0 
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Table 3A 
Comparison of immunoreactivity score among OL, OSMF, OLP and NOE 
Groups N 
Immunoreactivity scores 
Negative Mild Moderate Strong 
OL 15 
2 
(13.3%) 
6 
(40%) 
6 
(40%) 
1 
(6.7%) 
OSMF 15 
6 
(40%) 
3 
(20%) 
6 
(40%) 
0 
(0%) 
OLP 15 
2 
(13.3%) 
0 
(0%) 
12 
(80%) 
1 
(6.7%) 
NOE 15 
15 
(100%) 
0 
(0%) 
0 
(0%) 
0 
(0%) 
Total 60 
25 
(41.7%) 
9 
(15%) 
24 
(40%) 
2 
(3.3%) 
Significance P 
Value 
  0.01 (HS)*  
 
Table 3B 
Intergroup comparison of study samples based on IRS score 
Intergroup comparison Significance 
OL vs. OSMF 0.261 (NS)* 
OL vs. OLP 0.05 (S)* 
OSMF vs. OLP 0.05 (S)* 
*Chi Square Test  
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Table 4A 
Comparison of intracellular stain location among OL, OSMF, OLP and NOE 
Groups N 
Stain location patterns 
No 
expression 
Cytoplasmic Nuclear C + N 
OL 15 
0 
(0%) 
3 
(20%) 
11 
(73.3%) 
1 
(6.7%) 
OSMF 15 
0 
(0%) 
0 
(0%) 
13 
(86.7%) 
2 
(13.3%) 
OLP 15 
0 
(0%) 
2 
(13.3%) 
10 
(66.7%) 
3 
(20%) 
NOE 15 
13 
(86.7%) 
0 
(0%) 
2 
(13.3%) 
0 
(0%) 
Total 60 
13 
(21.7%) 
5 
(8.3%) 
36 
(60%) 
6 
(10%) 
Significance P 
Value 
 0.001 (VHS)*  
 
Table 4B 
Intergroup comparison of study samples based on intracellular stain location  
Intergroup comparison Significance 
OL vs. OSMF 0.173 (NS)* 
OL vs. OLP 0.535 (NS)* 
OSMF vs. OLP 0.273 (S)* 
*Chi Square Test   
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Table 5A 
Comparison of of survivin distribution in the epithelium of OL, OSMF, OLP and 
NOE 
Groups N 
Distribution of survivin immunoreaction 
No 
expression 
Basal 
Basal and 
Parabasal 
Entire 
Thickness 
OL 15 
0 
(0%) 
5 
(33.3%) 
9 
(60%) 
1 
(6.7%) 
OSMF 15 
0 
(0%) 
2 
(13.3%) 
13 
(86.7%) 
0 
(0%) 
OLP 15 
0 
(0%) 
0 
(0%) 
15 
(100%) 
0 
(0%) 
NOE 15 
13 
(86.7%) 
2 
(13.3%) 
0 
(0%) 
0 
(0%) 
Total 60 
13 
(21.7%) 
9 
(15%) 
37 
(61.7%) 
1 
(1.7%) 
Significance P 
Value 
  0.01 (HS)*  
 
Table 5B 
Intergroup comparison of the study samples based on stain distribution 
Intergroup comparison Significance 
OL vs. OSMF 0.22 (NS)* 
OL vs. OLP 0.02 (S)* 
OSMF vs. OLP 0.14 (NS)* 
*Chi Square Test 
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Table 6A 
Comparison of percentage of survivin immunopositivity among OL, OSMF, 
OLP and NOE 
Groups N 
Percentage of survivin immunopositive cells 
Nil <10% 10-29% 30-59% 60-100% 
OL 15 
0 
(0%) 
7 
(46.7%) 
7 
(46.7%) 
1 
(6.7%) 
0 
(0%) 
OSMF 15 
0 
(0%) 
8 
(53.3%) 
7 
(46.7%) 
0 
(0%) 
0 
(0%) 
OLP 15 
0 
(0%) 
2 
(13.3%) 
12 
(80%) 
1 
(6.7%) 
0 
(0%) 
NOE 15 
13 
(86.7%) 
2 
(13.3%) 
0 
(0%) 
0 
(0%) 
0 
(0%) 
Total 60 
13 
(21.7%) 
19 
(31.7%) 
26 
(43.3%) 
2 
(3.3%) 
0 
(0%) 
Significance 
P Value 
  0.01 (HS)*  
 
Table 6B 
Intergroup comparison of the study samples based on the percentage of survivin 
immunopositive cells 
Intergroup comparison Significance 
OL vs. OSMF 0.58 (NS)* 
OL vs. OLP 0.13 (NS)* 
OSMF vs. OLP 0.05 (S)* 
*Chi Square Test 
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Table 7A 
Comparison of staining intensity among OL, OSMF, OLP and NOE 
Groups N 
Staining Intensity Scores 
Negative Mild Moderate Strong 
OL 15 
0 
(0%) 
3 
(20%) 
5 
(33.3%) 
7 
(46.7%) 
OSMF 15 
0 
(0%) 
7 
(46.7%) 
6 
(40%) 
2 
(13.3%) 
OLP 15 
0 
(0%) 
2 
(13.3%) 
9 
(60%) 
4 
(26.7%) 
NOE 15 
13 
(86.7%) 
2 
(13.3%) 
0 
(0%) 
0 
(0%) 
Total 60 
13 
(21.7%) 
14 
(23.3%) 
20 
(33.3%) 
13 
(21.7%) 
Significance P 
Value 
  0.01 (HS)*  
 
Table 7B 
Intergroup comparison of the study samples based on intensity of staining 
Intergroup comparison Significance 
OL vs. OSMF 0.10 (NS)* 
OL vs. OLP 0.34 (NS)* 
OSMF vs. OLP 0.13 (NS)* 
*Chi Square Test 
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Table 8 
Summary tabulation 
Category/Groups 
All 3 
groups 
OL 
vs.OSMF 
OL 
vs.OLP 
OSMF 
vs.OLP 
IRS score HS NS S S 
Intracellular Stain location HS NS NS NS 
Layer distribution HS NS S NS 
Percentage of 
Immunopositivity 
HS NS NS S 
Intensity of staining HS NS NS NS 
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Color plates 
  
Fig 15A and 15B: Oral leukoplakia showing dysplastic changes in the epithelium 
and underlying connective tissue (H&E, 40X
Fig 15C and 15D: Oral Leukoplakia showing survivin immunopositivity in the 
b
Fig 15E: Oral Leukoplakia showing nuclear and cytoplasmic survivin 
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Color plate 15 - Oral Leukoplakia 
; 100X)
 
asal and suprabasal areas (100X; 200X) 
 
immunopositivity (400X) 
 
 
 
 
  
Color plate 16 
Fig 16A and 16B: Oral Submucous Fibrosis showing surface epithelium and 
underlying fibrous collagen bundles in the connective tissue (
Fig 16C and 16D: Oral Submucous Fibrosis demonstrating positive survivin 
immunoreactivity in the b
Fig 16E: Oral Submucous Fibrosis de
immunoreactivity in the nuclear and cytoplasmic compartments (400X)
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- Oral Submucous Fibrosis 
   
(H&E, 
asal and suprabasal areas (100X; 
 
monstrating positive survivin 
 
40X; 100X) 
 
200X) 
 
  
Fig 17C and 17D: 
immunoreactivity in the b
Fig 17E: Oral Lichen Planus showing
COLOR PLATES 
55 
Color plate 17 - Oral Lichen Planus 
  
 
  
Oral Lichen Planus showing positive survivin 
asal and suprabasal areas (100X; 
 
 nuclear survivin immunoreactivity (400X
 
Fig 17A and 17B: Oral Lichen Planus showing surface epithelium with basal 
layer degeneration and lymphocytic infiltration in the subepithelial connective
tissue (H&E, 40X; 100X)
 
200X) 
) 
  
Color plate 
Fig 18C and 18D: Survivin expression is absent in 
Fig 18E: Survivin expression is absent in normal oral epithelium
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18 - Normal Oral Epithelium 
 
normal oral epitheliu
200X) 
 
 
 
 
 
Fig 18A and 18B: Normal oral epithelium showing epithelial lining and
underlying fibrous connective tissue (H&E, 100X; 400X)  
 
m (100X; 
 (400X) 
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OPMD forms a family of clinical or histological alterations of oral epithelium that 
indicates a risk towards transformation into squamous cell carcinoma. Most oral 
cancers, though the exact number is unclear, are preceded by a potentially malignant 
disorder. The estimated global prevalence of OPMD varies from 1% to 5% with an 
average prevalence rate of 2.6% with regional and geographical variations.55 
Nevertheless, the prevalence rate was reported to be higher in Indian population 
ranging from 9% to 14.6%.56 Microscopic examination to identify the presence of 
epithelial dysplasia in a biopsy sample is currently the reference standard in the 
assessment of OPMD to assess the risk of developing oral squamous cell carcinoma. 
Dysplasia, meaning abnormal growth, is the term given to the histopathological 
changes associated with an increased risk of malignant transformation. Oral mucosal 
dysplastic changes are characterized by disturbance in epithelial stratification and 
maturation (architectural features) accompanied by cellular atypia (cytological 
features). 
OL, OSMF and OLP are suggested to have a premalignant potential with varying 
consistencies. Hence, it becomes imperative to analyze the premalignant features and 
malignant transformation potential of these lesions for early diagnosis and accurate 
treatment planning. The ability of a clinician to diagnose a lesion early is further 
enhanced by histopathology and molecular analytical techniques. A study by 
Warnakulasuriya et al stated that, despite the availability of many molecular markers 
for the diagnosis of OPMD, an accurate predictive assessment of the clinical behavior 
of OPMDs will depend on development of newer markers.57 
Carcinogenesis is a multistep process that predominantly involves an imbalance 
between the activation of oncogenes and inactivation of tumour suppressor genes. 
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Most tumours are the outcome of imbalance of regulatory mechanisms controlling 
cell cycle progression, cell death/viability balance, and apoptosis. Apoptosis has 
become an essential tool in cancer research and in establishing new cancer 
strategies.29 
Physiologic regulation of apoptosis plays a significant role in embryonic 
development, tissue morphogenesis, and homeostasis resulting in regulation of cell 
number and elimination of damaged cells. On the other hand, resistance to apoptotic 
stimuli is involved in cancer development and progression as well as in autoimmune 
disorders. Overexpression of IAPs is thought to be a primary mechanism through 
which tumor cells acquire resistance to apoptosis.  
Survivin, an IAP protein, which is of considerable focus in recent times, appears to 
play a role in maintaining the cancer cell vitality. Any interference in survivin 
function has resulted in defects in mitotic transition thereby inducing cell death.58 The 
role of survivin protein is unique, and have been shown to bind specifically to 
caspases-3 and -7 leading to inhibition of apoptosis in in-vitro system.59 Furthermore, 
Li et al reported that survivin expresses during the G2/M phase of the cell cycle and 
the disruption of survivin-microtubule interactions results in increased caspase-3 
activity and accelerated apoptotic cell death.25 Ito et al reported that hepatocellular 
carcinoma cell lines transfected with survivin show a significant decrease in cells in 
the Gap0/G1 phase and an increase in cells in the synthesis and G2/M phases.
60 These 
findings indicate that survivin protein expression may correlate not only with reduced 
apoptotic cell death but also with an increased proliferative activity of cancer cells. 
Survivin has been the focus of the scientific community following its selective 
expression in highly proliferating normal tissues and in cancers of various anatomical 
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parts of the human body. In OSCC, a high incidence of survivin overexpression has 
recently been reported.61 Another interesting finding is that high survivin expression 
correlates with poor survival rates, thus making it as a better prognostic marker.29 
In this study, an attempt was made to compare the expression of survivin in OPMD 
like OL, OSMF and OLP with NOE as control. Several studies have reported an 
absence of survivin expression in normal oral mucosal tissue specimens.15, 19, 20, 30, 43, 
62 The present study demonstrated negative immunoreactivity in majority of samples, 
but mild nuclear staining was observed in less than 10% of cells predominantly in the 
basal layer in 2 samples of NOE. This is in line with few reports where weak nuclear 
and cytoplasmic expression of survivin was found among sporadic cells of basal and 
parabasal layers in NOE.30, 63 The outcome was also consistent with earlier studies 
which stated that the scanty expression could be due to active mitotic figures. 15, 19, 20, 
30, 43, 62  
On the other hand, Negi at el has reported survivin positivity in almost 20 percent of 
normal tissue specimens and attributed this to higher proliferative capacity of these 
tissues.48 Likewise, Tanaka et al pointed out that the survivin immunoexpression in 
normal oral epithelium is due to the presence of active mitotic cells.31 It was 
demonstrated that survivin was present in normal hematopoietic cells, immune cells, 
vascular endothelial cells, polymorphonuclear neutrophils, T lymphocytes, 
melanocytes, keratinocytes, neurons, and other cells of the mammalian brain.38 In 
contradiction to our findings, a study by Chaiyarit et al demonstrated significant 
expression of survivin in NOE and attributed to processing errors in fixation, antigen 
retrieval techniques, types of primary antibodies and detecting systems.45 Similar 
DISCUSSION 
 
60 
 
observation was also reported by Lodi et al in which all samples of NOE showed 
varied survivin mRNA expression, typically lower level of expression.46 
The present study demonstrates survivin immunoreactivity in most cases of OL (87%) 
with 2 samples (one case each of mild and moderate dysplasia) showing negative IRS. 
This was comparatively higher, as earlier reports had survivin immunopositivity in the 
range of 33% to 65% for OL.13, 31, 32, 48 Some studies have demonstrated complete 
expression of survivin in epithelial dysplasia.20, 39, 44 The immunoreactivity varied 
from mild to moderate with a single case of histopathologically confirmed CIS 
demonstrating stronger expression. Majority of OL cases selected in this study were 
mildly dysplastic, while 3 of them had moderate dysplastic features. Gayathri et al 
demonstrated a progressive increase in survivin expression based on predominant 
staining pattern and histological grading.51 Although our study demonstrated stronger 
expression of survivin in one case of CIS, a correlation between the histological 
grading and survivin expression couldn’t be established based on the parameters 
measured in mild and moderate dysplasia, considering the small sample size utilized 
in this study. 
Survivin seems to exist in two subcellular pools, cytoplasmic and nuclear. Majority of 
OL samples in our study demonstrated nuclear expression of survivin (73.3%). 
Conversely, most studies had reported cytoplasmic expression of survivin in oral pre-
malignant lesions, especially oral leukoplakia.13, 19, 20, 29, 30, 31, 39 There are two 
different opinions regarding the significance of survivin nuclear positivity. Despite 
the fact that nuclear expression of survivin is an unfavorable factor for prognosis in 
various tumors and OPMDs occurring in humans, some authors have proposed 
survivin nuclear positivity as a favorable prognostic marker.19 However, the authors 
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demonstrated observer variance in analysing survivin expression in nucleus and 
cytoplasm and suggested varied analytical procedures like western blots and dilution 
of antibodies to establish any unusual observation. Stauber et al stated that survivin 
can traverse between the nucleus and cytoplasm and may play a cytoprotective role 
while in the cytoplasm and likewise play a role in cell division while in the nucleus. 
This bifunctional role of survivin is dependent on various factors like nuclear export 
receptors, chromosomal passenger complexes and basic amino acids.64 Grabowski et 
al demonstrated that the survivin was mainly localized in the cytoplasm of basal cells 
in normal squamous epithelium but nuclear survivin expression was found in high 
grade dysplasia of the esophageal tissue.65 While our study demonstrates increased 
expression of nuclear survivin, and minimal cytoplasmic expression, the prognostic 
significance of nuclear and cytoplasmic expression cannot be established with a small 
sample size. It is of utmost importance that a large scale study to analyse the 
prognostic outcome of nuclear or cytoplasmic survivin is advised in future to clear the 
ambiguous situation persisting at present. This could be considered as a shortcoming 
of our study due to the small sample size.  
Survivin was predominantly distributed in the basal and parabasal layers of OL. 
Nevertheless, it was localised in the parakeratin/keratin layers and the prickle cell 
layers in most studies.13, 19, 31, 32 Grabowski et al demonstrated that the limitation of 
survivin in the basal layers of esophageal epithelium is due to the role played by 
survivin in cellular proliferation.65  
Almost 46.7% of OL samples had survivin immunopositivity in less than 10% of 
cells. In 46.7% samples, survivin was expressed in 10-29% cells while a single 
sample showed positivity in 30-59% cells. No significant difference was noted in the 
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immunopositivity patterns between our study and earlier studies.13, 20, 30, 32, 36 While 
survivin immunopositivity cannot be considered as a valid end point to measure the 
expression considering the subjective bias, it was used as an indicator in earlier 
studies. 13, 20, 30, 32, 36  
This study demonstrated strong staining intensity in most samples (46.7%) of OL 
followed by moderate (33.3%) and mild (20%) staining intensity. Whereas the study 
by Gayathri et al demonstrated predominantly moderate (37%) staining intensity 
followed by mild (33%) and strong (17%) staining intensity in OL.51 While the 
moderate staining is consistent with this study, the staining intensity in other 
categories did not provide a consistent result. This could be attributed to the fact that 
the measure of staining intensity could not be considered as an endpoint measurement 
of survivin expression due to the significant variations present during sample 
collection, fixation, processing, staining and observation. 
Oluwadara et al demonstrated high expression levels of survivin in epithelial 
dysplastic lesions in comparison to OLP while our study demonstrated almost similar 
immunoreactivity for survivin in both OL and OLP.44  
A high potential for malignant transformation was demonstrated in OSMF cases by 
Murti et al66 and Ekanayaka et al.67 Murti et al stated that the malignant 
transformation rate rose from 4.5% to 7.6% with a 2-year increase in observation 
period.66 Zhou et al (2008) demonstrated 30% expression in early OSMF, 46.7% in 
moderate OSMF, and 66.7% in advanced stage of OSMF.42 Zhou et al, in another 
study in 2010, demonstrated 20% expression in early stages, 45% in moderate OSMF, 
and 65% in advanced stages of OSMF.15 While the percentage expression was 
progressively increasing as the OSMF progressed, the degree of survivin expression 
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(mean survivin score) did not alter significantly between different stages as the 
authors considered that the classification of OSMF into stages was based on the 
degree of fibrous change in subepithelial connective tissue and not based on the 
degree of dysplasia.15, 42 
In OSF and OSCC originated from OSMF tissues, survivin was mainly localized in 
the nucleus with different brown granules.15, 42 In our study, survivin location in 
OSMF cases was predominantly noted to be nuclear and distributed in the basal and 
parabasal layers in majority of the samples. However, the distribution pattern varied 
according to the stages of OSMF in previous studies. In the early and moderately 
advanced stage of OSMF, the survivin staining was weakly expressed in basal and 
prickle layer, while the advanced OSMF had stronger expression in basal, prickle and 
granulosal layer cells.15, 42 The intensity of survivin positivity was in accordance with 
the observation made by Zhou et al.15, 42  
The malignant potential of OLP varied from 0.4% to 4.9% in earlier studies.66, 68, 69, 70 
An increased occurrence of OSCC had been reported in cases of erosive and atrophic 
types of OLP.71, 72, 73 Earlier studies demonstrated survivin expression in OLP to be 
64.3%44, 97%45, and 95%50. The present study had survivin expression in 100% 
samples. The majority of cases showed moderate immunoreactivity in the basal and 
parabasal layers of epithelium while the study by Suganya et al demonstrated mild to 
moderate survivin expression predominantly in the basal layer.50 In the study by 
Chaiyarit et al, OLP demonstrated survivin expression in the nuclear compartment 
predominantly with one third cases demonstrating both nuclear and cytoplasmic 
positivity.45 Likewise, our study also reported survivin positivity predominantly in the 
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nuclear compartment in 66% samples, both nuclear and cytoplasmic compartments in 
20% samples and in cytoplasmic compartment in 14% of samples. 
The survivin staining intensity was moderate in 60% samples, strong in 27% samples, 
and mild in 13% of samples. No significant deviation has been noted in comparison 
with the previous studies.44, 45, 50 
Intergroup comparison of survivin expression between OL, OSMF and OLP was not 
performed in any of the earlier studies. Few studies compared the expression of 
survivin between two OPMD or between OPMD and OSCC with NOE as a control. 
Studies with intergroup analyses performed earlier includes Oluwadara et al (OL, 
OLP, OSCC and NOE),44 Zhou et al (OPMD, OSCC, and NOE),15 Zhou et al 
(OPMD, OSCC, and NOE),42 and Gayathri et al (OL, OSCC, and NOE).50 
Significant associations were demonstrated between the pathology under investigation 
against the NOE and OSCC in these studies.  
Intergroup comparison using IRS in our study revealed significant difference between 
OL and OLP and between OSMF and OLP. However, no significant difference was 
observed between OL and OSMF. While most of the OL lesions were cases of mild 
dysplasia, majority of the OLP cases were erosive OLP. It has been documented that 
the malignant potential amongst the OLP lesions is comparatively high in erosive 
OLP.69 The higher IRS scores in OLP group can be attributed to the fact that the 
lesions that were selected for IHC were predominantly erosive OLP and they indeed 
have a higher malignant potential than the cases of OL which were predominantly 
classified as mild dysplasia based on histopathology.  
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The distribution of survivin expression in different epithelial layers was insignificant 
between OL and OSMF and between OSMF and OLP but there was a significance of 
difference between OL and OLP. While the expression of survivin in majority of OL 
cases was noted to be in the basal and parabasal layers, almost 33% of OL cases 
showed expression restricted only to the basal layer of the epithelium. In contrast, all 
the cases of OLP showed expression in the basal and parabasal layers. There was one 
case of histopathologically confirmed CIS which showed expression across the full 
thickness of the epithelium. This shows that the expression of survivin indeed 
correlates with the progression of dysplastic features across the epithelium. In cases of 
OSMF, most of the cases showed expression in the basal and parabasal layers. It has 
been demonstrated in the earlier studies that about 7-26% occurrence of epithelial 
dysplasia in cases of OSMF.10, 66 Zhou et al has proposed for further studies related to 
the molecular mechanism of survivin overexpression in cases of OSMF.15, 42 
The mean immunopositivity showed significance between OSMF and OLP but was 
insignificant between the other two lesions. No significance could be evaluated 
between the groups based on staining intensity. Most cases of OLP (80%) showed 
positive expression in the 10-29% range while 50% cases of the OSMF group showed 
expression in less than 10% of the cells. This can be again attributed to the fact that 
the malignant transformation in OLP and OSMF are significantly different. This 
attains more importance as most OLP cases included in the study were erosive OLP 
and the 13% of OLP cases which showed expression in less than 10% of cells were 
reticular OLP. However, in a study by Hsue et al, malignant transformation potential 
of epithelial dysplasia was at 4.82%, OSMF at 1.9%, and OLP at 2.10%. However, 
the mean duration of transformation was significantly lower for OLP (14.7 months) as 
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compared to OSMF (52.3%) and epithelial dysplasia (28.2%).74 In another study by 
Ho et al, the malignant transformation of OPMDS were found to be 24.2% in 
epithelial dysplasia while none of the cases of OSMF underwent malignant 
transformation. Increased immunopositivity can be considered to demonstrate an 
increase in malignant transformation potential but as the measurement of 
immunopositivity alone is very subjective, further large scale studies may be required 
before arriving at a consensus.75  
In our study, significant difference was noted between OL, OSMF and OLP against 
the NOE as control. However, this differential expression of survivin in normal versus 
malignant tissue is a strong advocate for development of survivin-based cancer drugs. 
Therapeutic modality based on a survivin promoter was used to direct expression of 
other apoptotic genes selectively in tumor cells and it was demonstrated that using 
bax mutants in combination with survivin promoter for tumor-targeted suicide gene 
was effective in vitro.76 
Few shortcomings can be found in our study of which the significant one is the small 
sample size followed by convenient sampling of specimens from the available 
archival blocks. While the histopathological grading of OL, OSMF, and OLP was 
performed, uniform numbers of samples in each grade were unavailable and hence, an 
intralesional comparison of different histological grades with equal samples was not 
performed. However, we have correlated the survivin expression patterns with the 
available histopathological information. While the inclusion of three different lesions 
with NOE as a control did provide significant information regarding survivin and its 
role in malignant transformation, we advocate researchers to conduct a large scale 
study amongst the OPMDs to further enhance the knowledge regarding survivin 
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immunoexpression and its diagnostic and prognostic significance in each lesion and 
between different lesions.  
In recent times, various modalities of cancer therapeutics including antisense 
technology, dominant negative constructs, ribozyme technique and histone 
deacetylase inhibitors are being tested in various studies. Antisense technology 
includes usage of antisense oligonucleotides, small interfering RNAs, and short 
hairpin RNAs are being used to inhibit expression of target genes. Dominant negative 
mutants for survivin (eg. T34A) are developed based on the rationale where the 
mutants compete with regular cellular proteins for the target and inhibits the function 
of the survivin. Ribozyme (ribonucleic acid enzyme) have been developed to cleave 
the survivin mRNA which results in inhibition of translation and subsequent 
restriction of tumor growth. Evidence also suggests that histone deacetylases like 
clamydocin and LAQ824 downregulates survivin levels and induces apoptosis of 
tumor cells.77 
Conclusion 
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The oral cavity is a very important location for many reasons. It is easily accessible 
for inspection and sampling without any major risk to the patient. The need for 
advanced techniques makes it suitable for studying different cellular mechanisms. 
OPMDs in the mucosa are easy to detect and clearly visible to the healthcare provider. 
Thus, OPMDs provide us with an excellent model for studying the malignant 
transformation process and the development of cancer. It is very important to prevent 
malignant change in people diagnosed with OPMDs, but the hazard ratios of various 
OPMDs and the rate of malignant transformation are not well established. First and 
foremost, a detailed study of OPMDs with a prognostic marker established in various 
other premalignant disorders and cancers has to be evaluated. The rationale behind 
this study was to identify the significance of such a biomarker across the most 
common OPMD lesions based on different parameters.  
Comparison of survivin across OL, OSMF, OLP and NOE was done in this study. 
Survivin was not/minimally expressed in normal oral tissue samples, consistent with 
many studies which had repeatedly proved that survivin is not expressed in normal 
tissues that do not show high proliferative activity. Oral mucosa, especially gingiva, 
does not demonstrate a high proliferative activity except for few mitotic cells which 
showed positivity for survivin. Survivin was expressed in all the OPMDs including 
OL, OSMF and OLP. Significant difference was observed in the immunoexpression 
patterns of OPMD in comparison with NOE.  
As discussed earlier, the dysplastic changes and significant number of mitotic figures 
in the OPMDS resulted in an increased expression of survivin in comparison to the 
normal mucosal specimens. Significant difference was observed in the 
immunoreactivity patterns of OLP compared to OL and OSMF. Most OLPs which 
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were included in the study were of the erosive type while most OLs included in the 
study were mild dysplasias. This can be attributed to the significant difference of 
expression between OL and OLP. Considering the OSMF and OLP, OLP has been 
demonstrated to have a significantly higher malignant transformation potential than 
OSMF which can be attributed to the increased expression of survivin in OLP. 
Significant difference was observed in the distribution of survivin immunoexpression 
of OL compared to OLP. This can be probably due to the fact that majority of the 
mild dysplasia cases of OL demonstrated survivin expression only in the basal layers 
in comparison to the OLP cases, all of which demonstrated survivin expression in 
both the basal and parabasal layers.  
Significant difference was also found in the mean immunopositivity of OSMF 
compared to OLP. This may be due to the fact that most OLP cases included in the 
study were erosive OLP and the 13% of OLP cases which showed expression in less 
than 10% of cells were reticular OLP. However, in a significant number of OSMF 
cases, less than 10% cells showed survivin immunopositivity. OSMF is a disease of 
the connective tissue and epithelium may not show dysplastic changes until the later 
stages of the disease.  
To summarize, large studies are needed to corroborate the prognostic impact of 
survivin expression in OPMDs and OSCC, however, this dissertation suggests that 
survivin detection may provide a new tool to identify OPMDs in patients at high risk 
of unfavorable outcome. This is particularly relevant for the segregation of survivin 
expression in OPMD patients with an ambiguous histological outcome, the group for 
which new molecular indicators of dysplastic changes are needed with priority. On 
the other hand, development of anti-survivin molecules may provide a novel 
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therapeutic approach for patients by increasing the sensitivity of cells to apoptosis-
inducing stimuli.  
To conclude, the significant new knowledge forthcoming from this dissertation needs 
to be brought into the diagnostic component of oral cancer. The objective of 
healthcare providers is to reduce the morbidity and eliminate mortality of patients 
with OPMDs and OSCCs. 
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Immunoexpression of Survivin in Oral Leukoplakia group (Group 1) 
S.No Category Site Age Gender Intensity 
Immunoposit
ivity % 
Stain location Distribution IRS 
1 OL Buccal mucosa 45 Male Strong 30-59% Entire thickness 
Cytoplasmic and 
nuclear 
Severe 
2 OL Buccal mucosa 55 Male Mild 10-29% Basal Nuclear Mild 
3 OL Buccal mucosa 57 Male Strong <10% Basal Nuclear Mild 
4 OL Buccal mucosa 41 Male Moderate <10% Basal Nuclear Mild 
5 OL Buccal mucosa 65 Male Strong 10-29% Basal and Parabasal Nuclear Moderate 
6 OL Buccal mucosa 40 Male Strong 10-29% Basal and Parabasal Nuclear Moderate 
7 OL Gingiva 52 Male Strong 10-29% Basal and Parabasal Nuclear Moderate 
8 OL Lip 35 Male Moderate 10-29% Basal and Parabasal Cytoplasmic Moderate 
9 OL Buccal mucosa 56 Male Strong 10-29% Basal and Parabasal Nuclear Moderate 
10 OL Buccal mucosa 32 Male Moderate <10% Basal Nuclear Mild 
11 OL Buccal mucosa 67 Male Strong <10% Basal and Parabasal Nuclear Mild 
12 OL Buccal mucosa 44 Male Moderate <10% Basal and Parabasal Cytoplasmic Mild 
13 OL Buccal mucosa 57 Male Mild <10% Basal and Parabasal Cytoplasmic Negative 
14 OL Buccal mucosa 39 Male Moderate 10-29% Basal and Parabasal Nuclear Moderate 
15 OL Gingiva 43 Male Mild <10% Basal Nuclear Negative 
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Immunoexpression of Survivin in Oral Submucous Fibrosis group (Group 2) 
S.No Category Site Age Gender Intensity 
Immunopositivit
y % 
Stain location Distribution IRS 
16 OSMF Buccal mucosa 65 Female Strong 10-29% Basal and Parabasal 
Cytoplasmic and 
nuclear 
Moderate 
17 OSMF Buccal mucosa 40 Male Mild <10% Basal and Parabasal Nuclear Negative 
18 OSMF Buccal mucosa 60 Female Moderate 10-29% Basal and Parabasal Nuclear Moderate 
19 OSMF Buccal mucosa 34 Male Mild <10% Basal and Parabasal Nuclear Negative 
20 OSMF Buccal mucosa 55 Male Mild <10% Basal and Parabasal Nuclear Negative 
21 OSMF Buccal mucosa 57 Female Moderate 10-29% Basal and Parabasal Nuclear Moderate 
22 OSMF Buccal mucosa 50 Male Mild <10% Basal and Parabasal Nuclear Negative 
23 OSMF Buccal mucosa 47 Male Moderate 10-29% Basal and Parabasal Nuclear Moderate 
24 OSMF Buccal mucosa 40 Female Moderate <10% Basal and Parabasal Nuclear Mild 
25 OSMF Buccal mucosa 45 Male Mild <10% Basal Nuclear Negative 
26 OSMF Buccal mucosa 27 Male Moderate <10% Basal and Parabasal Nuclear Mild 
27 OSMF Buccal mucosa 65 Female Strong 10-29% Basal and Parabasal 
Cytoplasmic and 
nuclear 
Moderate 
28 OSMF Buccal mucosa 51 Female Moderate 10-29% Basal and Parabasal Nuclear Moderate 
29 OSMF Buccal mucosa 31 Male Mild 10-29% Basal and Parabasal Nuclear Mild 
30 OSMF Buccal mucosa 59 Female Mild <10% Basal Nuclear Negative 
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Immunoexpression of Survivin in Oral Lichen Planus group (Group 3) 
S.No Category Site Age Gender Intensity 
Immunopositiv
ity % 
Stain location Distribution IRS 
31 OLP Buccal mucosa 40 Female Strong 10-29% Basal and Parabasal C + N Moderate 
32 OLP Buccal mucosa 27 Female Strong 30-59% Basal and Parabasal C + N Severe 
33 OLP Buccal mucosa 56 Male Strong 10-29% Basal and Parabasal C + N Moderate 
34 OLP Buccal mucosa 34 Female Moderate 10-29% Basal and Parabasal Nuclear Moderate 
35 OLP Buccal mucosa 37 Female Mild <10% Basal and Parabasal Nuclear Negative 
36 OLP Tongue 48 Female Moderate 10-29% Basal and Parabasal Nuclear Moderate 
37 OLP Buccal mucosa 45 Female Moderate 10-29% Basal and Parabasal Cytoplasmic Moderate 
38 OLP Buccal mucosa 24 Male Moderate 10-29% Basal and Parabasal Nuclear Moderate 
39 OLP Buccal mucosa 44 Male Moderate 10-29% Basal and Parabasal Nuclear Moderate 
40 OLP Buccal mucosa 35 Female Moderate 10-29% Basal and Parabasal Cytoplasmic Moderate 
41 OLP Buccal mucosa 51 Male Mild <10% Basal and Parabasal Nuclear Negative 
42 OLP Buccal mucosa 38 Female Strong 10-29% Basal and Parabasal Nuclear Moderate 
43 OLP Buccal mucosa 47 Female Moderate 10-29% Basal and Parabasal Nuclear Moderate 
44 OLP Buccal mucosa 29 Male Moderate 10-29% Basal and Parabasal Nuclear Moderate 
45 OLP Buccal mucosa 43 Male Moderate 10-29% Basal and Parabasal Nuclear Moderate 
ANNEXURE 2 
 
Immunoexpression of Survivin in Normal Oral Epithelium group (Group 4 - Control) 
S.No Category Site Age Gender Intensity 
Immunopositivit
y % 
Stain location Distribution IRS 
46 NOE Buccal mucosa 27 Female Mild <10% Basal Nuclear Negative 
47 NOE Gingiva 45 Male Nil Nil Nil Nil Negative 
48 NOE Gingiva 25 Male Nil Nil Nil Nil Negative 
49 NOE Buccal mucosa 38 Female Nil Nil Nil Nil Negative 
50 NOE Gingiva 42 Female Nil Nil Nil Nil Negative 
51 NOE Buccal mucosa 29 Male Nil Nil Nil Nil Negative 
52 NOE Alveolar mucosa 52 Female Nil <10% Basal Nuclear Negative 
53 NOE Buccal mucosa 35 Male Nil Nil Nil Nil Negative 
54 NOE Buccal mucosa 26 Female Nil Nil Nil Nil Negative 
55 NOE Gingiva 23 Male Nil Nil Nil Nil Negative 
56 NOE Buccal mucosa 29 Male Nil Nil Nil Nil Negative 
57 NOE Gingiva 46 Female Nil Nil Nil Nil Negative 
58 NOE Gingiva 32 Male Nil Nil Nil Nil Negative 
59 NOE Alveolar mucosa 39 Female Nil Nil Nil Nil Negative 
60 NOE Gingiva 41 Female Nil Nil Nil Nil Negative 
